On May 4, 2018 Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) ("Cotinga" or the "Company"), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported the closing of a brokered private placement (the "Brokered Offering") and a non-brokered private placement (the "Non-Brokered Offering", and together with the Brokered Offering, the "Offering") for total proceeds of approximately CAD $2,010,000 (Press release, Cotinga, MAY 4, 2018, View Source [SID1234533155]). Pursuant to the Offering, the Company issued 5,289,900 units (the "Units") at a price of CAD $0.38 per Unit. Cotinga plans to use the net proceeds from the Offering to support the continued clinical development of COTI-2.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This private placement improves our balance sheet and provides the funds necessary to advance our lead asset, COTI-2, into clinical development as a combination therapy," said Alison Silva, President and CEO. "Specifically, these funds enable us to expand our ongoing Phase 1 trial to evaluate COTI-2 in combination with various standards-of-care in a wide spectrum of cancers. We expect to provide a clinical update on these efforts in the months ahead. This financing also allowed us to diversify our shareholder base as we were pleased to secure U.S.-based institutional support to lead the offering. We welcome our new investors, who comprised 65% of this round, into the Cotinga story. We remain confident advancing COTI-2 will be a meaningful value-driver for both patients and shareholders, and we thank all of our shareholders for their continued support."
Each Unit consisted of one common share of the Company (each, a "Common Share") and one Common Share purchase warrant (each, a "Warrant") of the Company. Each Warrant is exercisable for one Common Share (each, a "Warrant Share") at an exercise price of CAD $0.47 per Common Share for a period of 60 months from May 3, 2018 (the "Closing Date"). The Common Shares and Warrants issued by the Company pursuant to the Offering are subject to restrictions on resale in accordance with applicable Canadian and U.S. securities laws and the policies of the TSX Venture Exchange (the "TSXV"). Under Canadian securities laws, the Common Shares, Warrants and Warrant Shares are subject to a restriction on resale for a period of four months plus one day from the Closing Date. Certain U.S. subscribers have been granted the right to participate in an aggregate of up to 50% of any subsequent financing of the Company for a period of 12 months from the Closing Date. The Offering is subject to final acceptance of the TSXV.
Roth Capital Partners, LLC (the "Agent") acted as sole placement agent for the Brokered Offering in the United States. The Agent received: (i) a cash commission of CAD $89,775; (ii) 158,697 warrants to purchase Common Shares exercisable for a period of 60 months from the Closing Date at an exercise price of CAD $0.47 per Common Share; and (iii) a corporate finance fee of CAD $50,936.
Certain registered dealers and other persons qualified to receive a finder’s fee ("Finders") received, in relation to the Non-Brokered Offering: (i) a cash commission of CAD $10,260; and (ii) 27,000 warrants to purchase Common Shares exercisable for a period of 60 months from the Closing Date at an exercise price equal to CAD $0.47 per Common Share.
The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer for Press Release sale of securities or a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.